Indian pharmaceutical companies are set for a steady September quarter. Growth in the US generics market and domestic sales will drive performance. Companies like Apollo Hospitals, Lupin, and Aurobindo are expected to show strong results. Despite some cost pressures, the sector anticipates positive medium-term prospects. New product launches and expanding facilities will support earnings.
AU Small Finance Bank Q2 profit jumps 53% to Rs 858 crore
AU’s gross non-performing assets ratio fell 42 basis points (bps) to 1.99% at the end of September. This helped in 25% lower provision at Rs
October 24, 2026